TB screening and anti-TNFα treatment [3]

Thorax

Volumn 61, Issue 7, 2006, Pages 641-

  Dhasmana, D J ^a   Nash, J ^a   Bradley, J C ^a   Creer, D ^a  

^a ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI TNF ALPHA; ISONIAZID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

CHEMOPROPHYLAXIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LIVER FUNCTION TEST; LIVER TOXICITY; MEDICAL RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCREENING; TUBERCULIN TEST; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; HUMANS; MASS SCREENING; RHEUMATIC DISEASES; TUBERCULIN TEST; TUBERCULOSIS, PULMONARY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745852589     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2006.062372     Document Type: Letter

References (3)

1. Provenzano G, Ferrante MC, Simon G. TB screening and anti-TNFα treatment. Thorax 2005;60:613.
2. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment. Thorax 2005;60:800-15.
3. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998;53:536-45.